During Thursday’s trading session, the shares of Dishman Carbogen Amcis Limited zoomed 2.34%. The company’s current market capitalisation is Rs 3,991 crore.
Dishman Carbogen Amcis Ltd is involved in Contract Research and Manufacturing Services (CRAMS) as well as the manufacturing and distribution of marketable molecules, including speciality chemicals, vitamins, and disinfectants.
The product-wise breakdown of Dishman Carbogen Amcis Ltd’s revenue showcases that a significant portion, 77.7%, is derived from Contract Research & Contract Manufacturing (CRAMS). This is followed by revenue from Cholesterol & Vit D Analogues at 9.4%, and API (Active Pharmaceutical Ingredients) at 8.5%. Additionally, Quats & Generics contribute 4.4% to the company’s revenue.
When considering the geographical distribution of revenue, the majority, 98.29%, comes from the Rest of the World, while India accounts for a smaller share of 1.71%.
This breakdown illustrates the diversified revenue streams of Dishman Carbogen Amcis Ltd, with CRAMS being the primary revenue driver, and a significant portion of revenue generated from international markets.
Dishman Carbogen Amcis Ltd has a substantial pipeline of orders for its Contract Research and Manufacturing Services (CRAMS) activities, reflecting robust demand in the pharmaceutical industry, particularly in the areas of oncology and ADC (Antibody-Drug Conjugate) business worldwide.
Key growth drivers include operational enhancements at the company’s India sites and growth initiatives in its Swiss entity. These factors collectively position the company for continued expansion and success in the pharmaceutical manufacturing sector.
Mukul Mahavir Agrawal holds a noteworthy 5.23% stake in Dishman Carbogen Amcis Ltd as of December 2023.
Mukul Agrawal has emerged as a prominent figure in the Indian stock market. His investment approach is characterized by a blend of aggressiveness, meticulous analysis, and a willingness to take risks, particularly with penny stocks that exhibit the potential for significant gains. Notably, Agrawal maintains two distinct portfolios—one for long-term investments and another for trading purposes.
Such significant involvement by an ace investor like Agrawal serves to bolster the confidence of retail investors in the company’s prospects, potentially influencing their investment decisions positively.
Furthermore, the stock has witnessed significant buying activity as it has given multibagger returns of more than 117% in the last 1 year.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. The information is based on various secondary sources on the internet and is subject to change. Please consult with a financial expert before making investment decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
